Compass Rose Asset Management LP Grows Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Compass Rose Asset Management LP raised its stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 366.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,100,000 shares of the company's stock after purchasing an additional 1,650,000 shares during the period. Bausch Health Companies accounts for 6.9% of Compass Rose Asset Management LP's holdings, making the stock its 6th biggest holding. Compass Rose Asset Management LP owned 0.58% of Bausch Health Companies worth $16,926,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of BHC. Mountain Hill Investment Partners Corp. purchased a new position in Bausch Health Companies during the fourth quarter worth about $56,000. Bank of Nova Scotia purchased a new stake in shares of Bausch Health Companies during the fourth quarter worth about $83,000. One68 Global Capital LLC purchased a new position in shares of Bausch Health Companies during the fourth quarter valued at about $90,000. Balyasny Asset Management L.P. purchased a new stake in Bausch Health Companies in the fourth quarter worth $97,000. Finally, Alpine Global Management LLC purchased a new position in Bausch Health Companies during the fourth quarter valued at $114,000. Institutional investors own 78.65% of the company's stock.

Bausch Health Companies Stock Performance

Bausch Health Companies stock opened at $4.76 on Wednesday. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -39.66, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $9.85. The company's 50 day simple moving average is $5.94 and its 200-day simple moving average is $7.17.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The business had revenue of $2.56 billion during the quarter, compared to analysts' expectations of $2.51 billion. Equities analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BHC shares. Jefferies Financial Group reissued a "hold" rating and set a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada boosted their price target on Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. Finally, StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Bausch Health Companies presently has a consensus rating of "Hold" and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.